CD19 and non-Hodgkin lymphoma: A CD19-specific CART cell therapy has been shown to be effective in B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma (NHL) (Schubert et al., 2016).